The pathogenesis of neovascular age related macular degeneration (AMD) is multifactorial including inflammation and angiogenesis leading to choroidal neovascularization (CNV). Therapy against vascular endothelial growth factor (VEGF) has revolutionized the treatment of neovascular AMD. Intravitreal off-label use of bevacizumab proved to be safe. This literature review was conducted to study improvement in visual acuity, change in central retinal thickness (CRT), safety, pharmacodynamics, and possible resistance to intravitreal bevacizumab over a one-year period in eyes with neovascular AMD. We reviewed articles between 1997 and January 2010 that included at least 30 patients with AMD who received intravitreal bevacizumab monotherapy for at least 1 year. The mean number of letters gained, decrease in CRT, and number of injections were 8 letters, 125.3 µm, and 4.3 injections, respectively. Further, randomized prospective clinical trials are needed to determine the efficacy and safety of intravitreal bevacizumab in the treatment of neovascular AMD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08820538.2010.545100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab.
Front Med (Lausanne)
January 2025
Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy.
View Article and Find Full Text PDFIntravitreal AAV-IKV Mediated Delivery of Decorin Inhibits Choroidal Neovascularization, Fibrosis, Inflammation and Elevates Autophagy.
Exp Eye Res
January 2025
Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111. Electronic address:
Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. The exudative or wet form of AMD is caused by choroidal neovascularization (CNV) and subsequently a macular edema. Wet AMD can be effectively treated with anti-vascular endothelial growth factor (VEGF) therapies.
View Article and Find Full Text PDFFrom pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD.
Eye (Lond)
January 2025
Department of Medicine-Ophthalmology, University of Udine, Udine, Italy.
Objective: To evaluate the impact of evolving treatment paradigms for neovascular age-related macular degeneration (nAMD) by comparing outcomes between two patient cohorts treated with different anti-vascular endothelial growth factor (anti-VEGF) regimens over a decade apart.
Methods: This retrospective cohort study included 200 treatment-naive nAMD patients divided into two cohorts. Cohort 1 (2009-2010) was treated with a pro re nata (PRN) regimen, involving three initial monthly injections followed by as-needed treatments based on monthly monitoring.
Agreement between Color, Fluorescein Angiography, and SD-OCT in the Detection of Macular Fibrosis in Neovascular AMD.
Am J Ophthalmol
January 2025
Centre for Public Health, Faculty of Medicine and Health Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom. Electronic address:
Purpose: Color imaging is the accepted reference standard for detection of macular fibrosis in neovascular age-macular degeneration. Other imaging modalities of fluorescein angiography (FA) and spectral domain optical coherence tomography (SD-OCT) are also used but no formal agreement studies exist. We evaluated the agreement between fibrosis on colour, FA and SD-OCT-detected hyperreflective material (HRM) and their clinical relevance.
View Article and Find Full Text PDFAnalysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD.
Eye (Lond)
January 2025
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Purpose: To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer's recommended induction phase of treatment.
Methods: Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!